Novel approaches to inhibiting HIV-1 replication
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Considerable success has been achieved in the treatment of HIV-1 infection, and more than two-dozen antiretroviral drugs are available targeting several distinct steps in the viral replication cycle. However, resistance to these compounds emerges readily, even in the context of combination therapy. Drug toxicity, adverse drug-drug interactions, and accompanying poor patient adherence can also lead to treatment failure. These considerations make continued development of novel antiretroviral therapeutics necessary. In this article, we highlight a number of steps in the HIV-1 replication cycle that represent promising targets for drug discovery. These include lipid raft microdomains, the RNase H activity of the viral enzyme reverse transcriptase, uncoating of the viral core, host cell machinery involved in the integration of the viral DNA into host cell chromatin, virus assembly, maturation, and budding, and the functions of several viral accessory proteins. We discuss the relevant molecular and cell biology, and describe progress to date in developing inhibitors against these novel targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brown, D. A., & Rose, J. K. (1992) · Cell · doi:10.1016/0092-8674(92)90189-j · Cited by 2,921
Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease
Berger, E. A., Murphy, P. M., & Farber, J. M. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.657 · Cited by 2,180
HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots
Schröder, A. R. W., Shinn, P., Chen, H., Berry, C., Ecker, J. R., & Bushman, F. (2002) · Cell · doi:10.1016/s0092-8674(02)00864-4 · Cited by 1,832
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705 · cited 1×
“The fact that assembly inhibitors will target interacting surfaces that may be relatively flat and cover large areas, and are therefore problematic for drug discovery, represents a significant future challenge for the development of this class of antiretrovirals (Arkin and Wells, 2004).”
BackgroundTsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding
Garrus, J. E., von Schwedler, U. K., Pornillos, O. W., Morham, S. G., Zavitz, K. H., Wang, H. E., Wettstein, D. A., Stray, K. M., Côté, M., Rich, R. L., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00506-2 · Cited by 1,369 · cited 2×
“The importance of Tsg101 in HIV-1 budding was demonstrated by the findings that i) siRNAmediated depletion of this ESCRT-I component profoundly reduces virus budding (Garrus et al., 2001), ii) Tsg101 fusion to Gag compensates for p6 mutation (Martin-Serrano, Zang, and Bieniasz, 2001), and iii) overexpression of the N-…”
BackgroundThe tripartite motif family identifies cell compartments
Reymond, A., Meroni, G., Fantozzi, A., Merla, G., Cairo, S., Luzi, L., Riganelli, D., Zanaria, E., Messali, S., Cainarca, S., et al. (2001) · The EMBO Journal · doi:10.1093/emboj/20.9.2140 · Cited by 1,366 · cited 1×
“2) domain (Reymond et al., 2001).”
Göttlinger, H. G., Sodroski, J. G., & Haseltine, W. A. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.15.5781 · Cited by 841
Martin-Serrano, J., Zang, T., & Bieniasz, P. D. (2001) · Nature Medicine · doi:10.1038/nm1201-1313 · Cited by 710 · cited 1×
“…depletion of this ESCRT-I component profoundly reduces virus budding (Garrus et al., 2001), ii) Tsg101 fusion to Gag compensates for p6 mutation (Martin-Serrano, Zang, and Bieniasz, 2001), and iii) overexpression of the N-terminal, Gag-binding domain of Tsg101 exerts a dominant-negative…”
BackgroundCrystal Structure of Human Cyclophilin A Bound to the Amino-Terminal Domain of HIV-1 Capsid
Gamble, T. R., Vajdos, F. F., Yoo, S., Worthylake, D. K., Houseweart, M., Sundquist, W. I., & Hill, C. P. (1996) · Cell · doi:10.1016/s0092-8674(00)81823-1 · Cited by 706 · cited 2×
“The CypA portion of TRIM-Cyp binds CA (Gamble et al., 1996; Luban et al., 1993) and disruption of this interaction abolishes the restriction activity of TRIM-Cyp (Towers et al., 2003).”
BackgroundHIV-1 Integrase Forms Stable Tetramers and Associates with LEDGF/p75 Protein in Human Cells
Cherepanov, P., Maertens, G., Proost, P., Devreese, B., Van Beeumen, J., Engelborghs, Y., De Clercq, E., & Debyser, Z. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209278200 · Cited by 704 · cited 1×
“A role for LEDGF/p75 in lentiviral integration was first suggested by studies that identified an interaction between this protein and HIV-1 IN (Cherepanov et al., 2003; Emiliani et al., 2005).”
Background
Cited by
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic
Broder, S. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.10.002 · Cited by 520
HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention
Blair, W. S., Pickford, C., Irving, S. L., Brown, D. G., Anderson, M., Bazin, R., Cao, J., Ciaramella, G., Isaacson, J., Jackson, L., et al. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001220 · Cited by 291
Current status and challenges of antiretroviral research and therapy
Esté, J. A., & Cihlar, T. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2009.10.007 · Cited by 277
Structural and functional insights into the HIV-1 maturation inhibitor binding pocket
Waki, K., Durell, S. R., Soheilian, F., Nagashima, K., Butler, S. L., & Freed, E. O. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002997 · Cited by 71
“As controls WT and SP1-T8A, a mutant that exhibited full susceptibility to BVM [5] were included.”
BackgroundResultSelf-citationNHEJ pathway is involved in post-integrational DNA repair due to Ku70 binding to HIV-1 integrase
Knyazhanskaya, E., Anisenko, A., Shadrina, O., Kalinina, A., Zatsepin, T., Zalevsky, A., Mazurov, D., & Gottikh, M. (2019) · Retrovirology · doi:10.1186/s12977-019-0492-z · Cited by 46
Metadata
- Authors
- Adamson, C. S., & Freed, E. O.
- Venue
- Antiviral Research
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 85
- Issue
- 1
- Pages
- 119-141
- ISSN
- 0166-3542 (ISSN-L)
- OpenAlex
- W2006771360
- Cited by
- 144
- References
- 57
- FWCI
- 11.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel approaches to inhibiting HIV-1 replication. https://app.cochat.ai/papers/10.1016/j.antiviral.2009.09.009
- The paper
- Adamson, C. S., & Freed, E. O. (2010). Novel approaches to inhibiting HIV-1 replication. Antiviral Research. https://doi.org/10.1016/j.antiviral.2009.09.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.